A Safety Study of NNZ-2566 in Patients With Rett Syndrome

Rett Syndrome Clinical Trial

Official title:

A Phase II Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Escalation Study of NNZ-2566 in Rett Syndrome

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01703533
• Other study ID #: Neu-2566-RETT-001
• Status: Completed
• Phase: Phase 2
• First received: October 4, 2012
• Last updated: January 31, 2018
• Start date: March 2013
• Est. completion date: September 2014

Study information

• Verified date: January 2018
• Source: Neuren Pharmaceuticals Limited
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to determine whether NNZ-2566 is safe and well tolerated in the treatment of Rett Syndrome in adolescent and adult females.

Description:

Rett Syndrome is a developmental disorder primarily if not exclusively affecting females. The disorder is characterized by apparent normal development in early infancy (6-18 months), followed by a period of regression with onset of systemic and neurological signs. The CNS symptoms of Rett Syndrome include learning disability, autism and epilepsy and these can be severe and highly debilitating. Affected individuals also show signs of autonomic dysfunction, reflected in cardiovascular and respiratory abnormalities. There is no currently effective treatment for Rett Syndrome.

This study will investigate the safety and tolerability of treatment with oral administration of NNZ-2566 at 35 mg/kg or 70 mg/kg BID in adolescent or adult females with Rett Syndrome. The study also will also investigate measures of efficacy during treatment.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 67
• Est. completion date: September 2014
• Est. primary completion date: September 2014
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 16 Years to 45 Years

Eligibility

Inclusion Criteria:

• Diagnosis of Rett Syndrome with proven mutation of the MeCP2 gene

• Age 16 to 45 years

• Severity rating of between 10 and 36 (Rett Syndrome Natural History/Clinical Severity Scale)

• Concomitant medications must be stable for >4 weeks prior to enrollment. The following concomitant medications are permitted: anticonvulsants which do not have liver inducing effects; beta-blockers; medications for the treatment of gastroesophageal reflux disease (GERD); medications for the treatment of chronic respiratory conditions such as asthma; medications for the treatment of anxiety, of depression and of psychosis, hormonal contraceptives. Melatonin for difficulties with sleep onset.

• Ability to swallow study medication provided as a liquid solution, or via gastrostomy tube

Exclusion Criteria:

• No detectable abnormality of the EEG during screening period

• Actively undergoing regression

• QTcF exclusions (any of the following): baseline/screening QT/QTcF interval of 450 msec; history of risk factors for torsade de pointes (e.g. heart failure, hypokalemia (serum potassium at screening < 3.0 mmol/L) or family history of long QT syndrome; QT/QTcF prolongation previously or currently controlled with medication

• Current treatment with insulin

• Hgb A1C values outside the normal reference range at screening

• Current or past treatment with IGF-1

• Current or past treatment with growth hormone

• Current treatment with N-methyl-D-aspartate (NMDA) antagonists

• Current or planned use of non-medication based interventional therapy during the period of the study (defined as 4-6 week screening period followed by 4 week dosing and 2 week follow-up period)

• Current clinically significant cardiovascular, renal, hepatic or respiratory disease

• Gastrointestinal disease which may interfere with the absorption, distribution, metabolism or excretion of the the study medication

• History of, or current cerebrovascular disease or brain trauma

• History of, or current significant endocrine disorder e.g. hypo or hyperthyroidism or diabetes mellitus

• History of, or current malignancy

• Clinically significant abnormalities in safety laboratory tests, vital signs or ECG, as measured at screening or baseline

• Confirmed pregnancy

• Significant hearing and/or visual impairment that may affect ability to complete the test procedures

• Enrollment in another clinical trial within the previous 30 days

• Previously randomized in this clinical trial

• Allergy to strawberries

Related Conditions & MeSH terms

• Rett Syndrome
• Syndrome

Intervention

Drug:
• NNZ-2566
Glycyl-L-2-Methylpropyl-L-Glutamic Acid (NNZ-2566) supplied as a lyophilized powder (2g in 50mL vials) for reconstitution with strawberry flavored solution 0.5% v/v in Water for Injection.
• Placebo
Strawberry flavored solution and Water for Injection

Locations

Country	Name	City	State
United States	University of Alabama	Birmingham	Alabama
United States	Baylor School of Medicine	Houston	Texas
United States	Gillette Children's Specialty Healthcare	Saint Paul	Minnesota

Sponsors (4)

Lead Sponsor	Collaborator
Neuren Pharmaceuticals Limited	Baylor College of Medicine, International Rett Syndrome Foundation, Texas Children's Hospital

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Pharmacokinetics	The following pharmacokinetic measures will be calculated from NNZ-2566 concentrations in whole blood: Tmax, Cmax (peak), Cmin (trough), CAV at steady state, T1/2 and AUC.	Baseline through to Day 40
Primary	Adverse events	Incidence of adverse events (AE), including Serious adverse events (SAE), will be evaluated between the two NNZ-2566 doses and placebo. SAEs will be examined from randomization through to Day 40. AEs will be examined from dosing through to Day 40.	Through to Day 40
Secondary	Change in EEG activity	Absolute change in the number of spikes in the EEG per hour during the awake state will be calculated for each subject between baseline (pre-treatment), during treatment (Days 1 thru 4, 14 and 26) and after treatment (Day 40).; Absolute change in the power of frequency bands in the EEG over an hour in the awake state as determined by the Fast Fourier method will be calculated for each subject between baseline (pre-treatment), during treatment (Days 1 thru 4, 14 and 26) and after treatment (Day 40).; Changes in the frequency of the characteristic repetitive stereotypic hand movements during wakefulness will be calculated for each subject between baseline (pre-treatment), during treatment (Days 1 thru 4, 14 and 26) and after treatment (Day 40).	Baseline through to Day 40
Secondary	Behavior	The following measures will be assessed at baseline and Day 26 and the changes compared between active and placebo groups: Symptom severity according to the Rett Syndrome Natural History Motor Behavior Assessment (MBA), Clinical Severity Scale (CSS), Aberrant Behavior Checklist (ABC), Vineland Adaptive Behavior Scale (VABS), and Clinical Global Impression of Severity (CGI-S).; The following assessments will be undertaken at the additional time points specified: CGI-S (screening, baseline, Days 5, 14, 26, and 40), CGI-I (Days 5, 14, 26, and 40), MBA (Baseline, Days 26 and 40), CSS (screening, baseline, Days 26, and 40).	Baseline through to Day 40
Secondary	Physiological changes	Changes in autonomic function, i.e. respiratory rhythm, hyperventilation, apneas, oxygen desaturation, and heart rate variation will be calculated between baseline (pre-treatment), during treatment (Days 1 thru 4, 14 and 26) and after treatment (Day 40).	Baseline through to Day 40
Secondary	Global and Functional outcome Measures	Global outcome as measured by the change in scores on the Rett Syndrome Clinical Severity Score (CSS), The Rett Syndrome Motor-Behavior Assessment Scale (MBA), and the Clinical Global Impression - Severity and Improvement scales (CGI-S and -I) from baseline, during treatment, and post treatment.; Changes in caregiver assessment of the top three causes for concern as assessed via a Visual Analogue Scale (VAS) will be evaluated for each subject between baseline (pre-treatment), during treatment (Day 26) and after treatment (Day 40).; Changes in the Aberrant Behavior Checklist (ABC) and Vineland Adaptive Behavior Scales (VABS) will be calculated for each subject between baseline (pre-treatment), and during treatment (Day 26).	Baseline through to Day 40